Sun, Mar 1, 2015, 12:40 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Oct 30, 2013 5:26 PM Flag

    NCCN listing in RET fusion NSCLC

    Good call, Ernie....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This one is hot off the presses. Non-Small Cell Lung Cancer Version 1.2014 has a new chart added on page NSCL-G that lists Cabo (and only Cabo) as a class 2a recommendation for REt gene fusion driven cancer. This listing is subsequent to a sponsor request, so EXEL had to apply for it.

      A 2a recommendation should get past most reimbursement barriers. The problem here though is that the system is not set up to screen for these patients. Dr Mark Kris talks about moving toward a comprehensive genetic screening test as a standard tool for all initial diagnoses. Search for NCCN Gives Nod to Dabrafenib for NSCLC - Medscape. Such a test would do a much better job of identifying and capturing these patients for Cabo treatment. EXEL still needs to pursue FDA approval and claim the "high ground" to protect this new revenue source and lock up the unmet need before any potential competitors.

    • Gisela M. Schwab - Executive Vice President and Chief Medical Officer:
      "To your first question what is viewed as a robust response rate, I think that is certainly the experience has set an example there so in the order 50% plus, minus."
      I may be wrong, but I recall the 3 cases in MSK (in Cancer Discovery) plus one separate Japanese case, there were 3 of 4 respond to Cabo treatment, and the last one may also partially respond to Cabo. So the "robust response rate" should be at least 75%.

      Sentiment: Strong Buy

    • wilderguide did Erine just make a post on NCCN listing in RET fusion NSCLC? If he did I'am not getting it.What did he say besides that?

2.930.000(0.00%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.